Cyclooxygenase-2 inhibitors and prostate cancer

Lancet Oncology

Volumn 8, Issue 10, 2007, Pages 859-860

  James, Nicholas ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROSTATE SPECIFIC ANTIGEN; ROFECOXIB;

ADENOMATOUS POLYP; ANTINEOPLASTIC ACTIVITY; CANCER INCIDENCE; CANCER INHIBITION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COLORECTAL CANCER; DRUG TARGETING; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HUMAN; LETTER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN SYNTHESIS INHIBITION; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 34748827978     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(07)70291-7     Document Type: Letter

References (11)

1. Hawkey C. COX-2 inhibitors. Lancet 353 (1999) 307-314
2. Taketo M. Cyclooxygenase-2 inhibitors in tumorigenesis (part II). J Natl Cancer Inst 90 (1998) 1609-1620
3. Taketo M. Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst 90 (1998) 1529-1536
4. Nelson J., and Harris R. Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case-control study. Oncol Rep 7 (2000) 169-170
5. Roberts R., Jacobson D., Girman C., Rhodes T., Lieber M., and Jacobsen S. A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. Mayo Clinic Proc 77 (2002) 219-225
6. Masferrer J., Leahy K., Koki A., et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60 (2000) 1306-1311
7. Arber N., Eagle C., Spicak J., et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 355 (2006) 885-895
8. Bertagnolli M., Eagle C., Zauber A., et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355 (2006) 873-884
9. Kerr D., Dunn J., Langman M., et al. Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. N Engl J Med 357 (2007) 360-369
10. Khor L., Bae K., Pollack A., et al. COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial. Lancet Oncol 8 (2007) 912-920
11. Solomon S., Pfeffer M., McMurray J., et al. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 114 (2006) 1028-1035